Protopic Shortage: What Providers and Prescribers Need to Know in 2026

Protopic (tacrolimus ointment 0.03% and 0.1%) remains one of the most clinically important topical immunomodulators for moderate to severe atopic dermatitis, particularly for patients requiring treatment on sensitive skin areas such as the face, eyelids, neck, and skin folds. As of 2026, Protopic is not on the FDA or ASHP formal drug shortage lists, but prescribers continue to report patient challenges accessing the medication — driven by a combination of pharmacy-level supply inconsistencies, payer barriers, and cost.

This guide is intended for dermatologists, allergists, pediatricians, and other prescribers managing patients on Protopic or considering its initiation. It covers current supply status, prescribing considerations, insurance landscape, and alternative escalation pathways.

Current Supply Status for Prescribers

As of Q1 2026, there is no FDA-listed or ASHP-listed shortage for tacrolimus topical ointment (either brand Protopic or generic). Generic tacrolimus ointment is available from multiple approved manufacturers, including Padagis (formerly Perrigo) and others. Overall supply is reasonably stable.

However, prescribers should be aware that:

Localized stockouts occur regularly, especially for the pediatric 0.03% strength

Brand-name Protopic has a smaller distribution footprint than generic alternatives

Seasonal demand fluctuations (fall/winter eczema season) can temporarily deplete stock at high-volume pharmacies

Writing prescriptions as 'tacrolimus ointment 0.03% [or 0.1%] — dispense as written or generic' will expand pharmacy options for your patients

Insurance and Prior Authorization Landscape in 2026

Prior authorization (PA) remains a significant access barrier for Protopic in 2026. Because the FDA classifies topical calcineurin inhibitors as second-line agents for atopic dermatitis — appropriate only when other treatments have failed or are not tolerated — most payers require documented step therapy.

Typical PA requirements include:

Trial and documented failure (or contraindication) of at least one low-to-medium potency topical corticosteroid

Confirmed diagnosis of atopic dermatitis (ICD-10: L20.x series)

For pediatric patients: documentation of age-appropriate strength (0.03% for ages 2–15)

Some payers additionally require failure of Elidel (pimecrolimus) before approving Protopic

Key PA documentation tip: Specifically document why topical steroids are not appropriate (e.g., 'lesions involve bilateral periorbital skin and eyelids — high risk for ocular adverse effects with topical corticosteroids; tacrolimus ointment indicated as steroid-sparing therapy'). This framing often streamlines PA approval.

Off-Label Use: Vitiligo and Beyond

Topical tacrolimus is widely used off-label for several dermatologic conditions, most notably vitiligo. Evidence supports tacrolimus 0.1% ointment for repigmentation in non-segmental vitiligo, particularly on the face and neck. A 2024 expert consensus from the Pigmentary Disorders Society recommends topical tacrolimus as one of the first-line topical agents for vitiligo treatment.

Other evidence-supported off-label uses include: allergic contact dermatitis, seborrheic dermatitis, lichen sclerosus, facial psoriasis, rosacea, and cutaneous lupus erythematosus. When prescribing off-label, document the clinical rationale clearly — insurers are unlikely to cover off-label indications, and patients may need to pay out of pocket.

Black Box Warning: Counseling Points for Patients

Protopic carries an FDA boxed warning regarding potential cancer risk (skin cancer and lymphoma). The causal link has not been established in clinical studies, and a 2021 long-term European cohort study (the JOELLE study) showed no significant increase in cancer risk with topical tacrolimus use. However, prescribers must provide the Medication Guide to patients with each fill and document that risks and benefits have been discussed.

Counseling points to emphasize:

Use only on affected areas; do not apply to healthy skin

Avoid continuous long-term uninterrupted use; use intermittently and stop when disease is controlled

Sun protection is important during treatment

Not for use in children under 2 years

Avoid use in patients with compromised immune systems or certain genetic skin disorders (Netherton syndrome, etc.)

When Protopic Is Unavailable: Escalation Pathway

If a patient cannot access Protopic:

First, ensure prescription reads 'tacrolimus ointment' (not brand-only) to maximize pharmacy options

For mild-moderate disease: consider pimecrolimus 1% cream (generic Elidel) as a bridge — similar mechanism, widely available

For moderate-severe disease with facial/sensitive-area involvement: consider ruxolitinib cream (Opzelura) for ages 12+ or dupilumab (Dupixent) for ages 6 months+

Short-course low-potency topical corticosteroids remain appropriate bridges for body sites without atrophy risk

Helping Your Patients Find Protopic

When patients are struggling to locate Protopic at local pharmacies, medfinder for providers is a resource worth knowing about. medfinder calls pharmacies on a patient's behalf to identify which ones have a specific medication in stock, saving patients hours of calling around on their own. Refer patients to medfinder.com to use the service. Also see our patient-facing guide on alternatives to Protopic.